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Abstract 
The studies of cardiac fibroblasts mitochondria activity using fluorescence probe MitoTracker Red CMXRos (Thermo 
Fisher Scientific, USA) and proliferation capacity with MTT assay (Thermo Fisher Scientific, USA) were carried out under 
the influence of antihypoxant (trimetazidine) and anticancer (doxorubicin, cytosar) medicinal preparations. It was revealed 
that medicinal preparations from the antitumor antibiotics group decreased mitochondria activity regardless of the cell state 
unlike antitumor metabolites. Medicinal preparation trimetazidine increases cardiac fibroblasts mitochondrial activity. 
Keywords: Cardiac Fibroblasts, Mitochondria, MTT Assay, Antitumor Agent, Antibiotic, Antimetabolite, Antihypoxant, 
Cytotoxicity. 
Background 
Currently, preclinical studies at the molecular [1-
3], cellular [4-7], organ [8, 9], organism levels [10-
14], along with bioequivalence studies, therapeutic 
equivalence, and safety are an integral part of the 
development of new medicinal preparations [15, 16]. 
It is known that heart function is regulated via 
interaction of two main types of cells: cardiomyocytes 
(CMs) and cardio fibroblasts (CFs). 
 Heart fibroblasts are located in the layers of 
cardiomyocytes and play an important role during 
physiological functioning of the organ and at 
pathological states (hypertension, myocardial 
infarction, heart failure) [17, 18].  
Because of cardiac fibroblasts specific localization 
these cells could activate reparative regeneration 
processes in myocardium during its damage due to 
increasing of paracrine activity and maintaining of 
extracellular matrix (ECM) homeostasis [19-24, 31]. 
 At the same time, positive effect of treatment 
during myocardial damage directly depends on the 
correct pharmacotherapy strategy, which is aimed at 
both activation and inhibition of the activity of cardiac 
fibroblasts.  
Energy saving effect of trimetazidine, cytoflavin, 
phosphocreatine and meldonium during experimental 
myocardial ischemia was revealed [25], whereas in 
cute heart failure trimetazidine played an important 
role in preventing myocardial fibrosis [26, 32]. 
Thus, study of morph functional state of cardiac 
fibroblasts under the influence of various medicinal 
preparations is an important to understand heart path 
physiology when safe and effective methods of drug 
therapy are developing. 
Aim 
The aim of the research is to study cardiac 
fibroblasts mitochondria activity under the influence 
of antihypoxant and anticancer medicinal 
preparations. 
Material and Methods 
Experimental researches with laboratory animals 
were carried out in accordance with international 
requirements [27]. Cardiac fibroblasts were isolated 
from newborns 6 day old rats’ hearts ventricles.  
The tissue was incubated in enzymes solution 
(trypsin/collagenase Type I, Thermo Fisher Scientific, 
USA). The cells released from the tissues fragments 
due to repeatedly pipetting.  
The cells were cultured in 25 cm2 culture flasks 
(SPL Life Sciences Co., Ltd., Korea) in culture 
medium DMEM/F12 (Thermo Fisher Scientific, 
USA) containing 10% fetal calf serum (Biosera, 
France) and gentamicin (50 µg/mL) in CO2-incubator 
at 37°С, 100 % humidity and 5% СO2.  
After 7 days of cultivation the cells were detached 
using trypsin and the number of cells in suspension 
was counted.  
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Then the cells were placed in the wells of 24-well 
plate (SPL Life Sciences Co., Ltd., Korea) in the 
amount of 3.5x105 cells per well and in the wells of 
96-well plate (SPL Life Sciences Co., Ltd., Korea) in 
the amount of 5x104 cells per well.  
Plate’s wells with DMEM/F12 culture medium 
(Thermo Fisher Scientific, USA) without serum were 
used as positive control, wells with DMSO solution 
(cat. 85190 Thermo Fisher Scientific, USA) at a 
concentration of 5% were used as negative control. 
During the research the following medicinal 
preparations were used: doxorubicin (Teva 
Pharmaceutical Industries, Ltd., Israel, 60 mg/m2) – 
antitumor anthracycline antibiotic which exhibits high 
antimitotic activity; cytosar / cytarabine (PFIZER, 
Inc., USA, 100 mg/m2) – antitumor antimetabolite, 
DNA synthesis inhibitor; trimetazidine (Teva 
Pharmaceutical Industries, Ltd., Israel, 60 mg/4,8 L) – 
antihypoxant, which improves oxygen utilization and 
reduces the need for it.  
All the medicinal preparations were added into 
culture medium DMEM/F12 (Thermo Fisher 
Scientific, USA) which did not contain serum. 
After 24 hours of cultivation medicinal 
preparations were added to cells which were growing 
in the wells of 24-well plate and cultured during 24 
hours.  
Then fluorescent dye MitoTracker Red CMXRos 
(Thermo Fisher Scientific, USA) at a final 
concentration of 200 µM was added to the wells, cells 
were cultured during 30 minutes in CO2-incubator.  
The fluorescent dye accumulates in mitochondria 
due to mitochondrial membrane negative charge, and 
because of the presence of chloromethyl group, the 
dye binds to the thiols of proteins and peptides in the 
mitochondrial matrix.  
Intensity of mitochondria fluorescence was studied 
with fluorescence microscope ECLIPSE Ti-S 
(NIKON, Japan) and software Nikon EZ-C1 
FreeViewer (NIKON, Japan) in 10 visual fields. 
Also, after 24 hours of cultivation medicinal 
preparations were added to cells which were growing 
in the wells of 96-well plate and cultured during 24 
hours. Then 20 µL of MTT reagent (3-(4, 
5dimethylthiazol-2-y1)-2,5-diphenyl tetrazolium  
bromide, cat. M6494, Thermo Fisher Scientific, USA) 
was added into each well.  
The cells were incubated with the reagent during 2 
hours in the conditions of CO2-incubator at 5% CO2 
and 37⁰C. At the end of incubation period the plate 
was removed from CO2-incubator, the solution was 
aspirated from the wells and DMSO solution (cat. 
D12345 Thermo Fisher Scientific, USA) was added. 
The plate was carefully shaken to dissolve formazan 
crystals.  
Optical density of solutions was measured using 
ELISA photometer MultiskanFC (Thermo Fisher 
Scientific, USA) at 540 nm (reference absorbance 
value was 620 nm). The survival rate of cardiac 
fibroblasts was calculated using formula (1): (𝑂𝑂𝑂𝑂  𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒  𝑤𝑤𝑒𝑒𝑒𝑒𝑒𝑒𝑤𝑤 −𝑂𝑂𝑂𝑂  𝑒𝑒𝑒𝑒𝑚𝑚𝑒𝑒𝑚𝑚𝑒𝑒 )(𝑂𝑂𝑂𝑂  𝑐𝑐𝑐𝑐𝑒𝑒𝑒𝑒𝑒𝑒𝑐𝑐𝑒𝑒  𝑤𝑤𝑒𝑒𝑒𝑒𝑒𝑒𝑤𝑤 −𝑂𝑂𝑂𝑂  𝑒𝑒𝑒𝑒𝑚𝑚𝑒𝑒𝑚𝑚𝑒𝑒 )  ×100% ,                              (1) 
Where OD – optical density. 
Statistical data processing was performed using 
software Statistica 6.0. 
Results and Discussion 
During the research low mitochondria fluorescence 
intensity was revealed in the positive control group 
51.52±10.02 a.u. in comparison with the negative 
control group 57.98±11.85 a.u., which possibly could 
be connected with the achievement by the cells 
“plateau” stage at which the cell life processes slow 
down due to impossibility of further proliferation due 
to the lack of nutrients and free space in the well, 
while cell morphology was not changed (Fig. 1). 
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Figure -1: Positive control group (A) and negative 
control group (B) cardiac fibroblasts fluorescence 
intensity. Magnification Х 100. 
Decrease of fluorescence intensity was revealed in 
the group of cells where doxorubicin was added – 
53.24±9.61 a.u. The differences are not significant in 
comparison with positive and negative control groups, 
which probably are connected with the cytotoxic 
effect of the preparation.  
The morphology of the cells was greatly changed, 
there were cells detached from the bottom of the well 
(Fig. 2). The mechanism of cytotoxic effect of 
anthracycline antibiotics is mainly associated with 
nucleic acids synthesis inhibition by intercalation 
between pairs of nitrogenous bases, damaging of 
secondary helical DNA due to interaction with 
topoisomerase II, as well as binding with cell 
membrane lipids, accompanied by changes in ion 
transport and cellular functions. 
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Figure- 2: Positive control group (A) and group with 
doxorubicin adding (B) cardiac fibroblasts 
fluorescence intensity. Magnification Х 100. 
The opposite effect was discovered in groups with 
adding of cytosar and trimetazidine medicinal 
preparations. Fluorescence intensity increased to 
110.116 ± 24.24 a.u. and to 117.72±19.35 a.u. 
respectively, the differences were significant at 
р≤0.01 in comparison with both positive and negative 
controls, the morphology of cells was not changed 
(Fig. 3). Cytostatic effect of cytosar was associated 
with impaired synthesis of nucleic acids (DNA, 
RNA). Being a phase-specific antimetabolite cytosar 
predominantly acts in the S-phase of the cell cycle in 
which DNA replication occurs. Trimetazidine has a 
cytoprotective effect due to increasing of energy 
potential, activation of oxidative decarboxylation and 
rationalization of oxygen consumption (enhancement 
of aerobic glycolysis and blockade of fatty acid 
oxidation). Cytosar did not show cytotoxic effect, 
because the cells were at a “plateau” stage and did not 
divide. As an antimetabolite it possibly triggered the 
processes which were connected to activation of thiol 
groups of proteins and peptides in mitochondrial 
matrix. Increasing of fluorescence intensity during 
trimetazidine application is associated with glycolysis 
activation within the cell. 
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Figure- 3: Group with cytosar (A) and group with 
trimetazidine adding (B) cardiac fibroblasts 
fluorescence intensity. Magnification Х 100. 
The highest survival rate of cardiac fibroblasts was 
revealed for the cells incubated with culture medium 
which contained cytosar – 82.86%, the differences 
were significant in comparison with negative control 
group (р≤0.01). Also, the high survival rate of cells 
was revealed for cardiac fibroblasts cultured with 
trimetazidine – 80%, the differences were significant 
in comparison with negative control (р≤0.01). When 
the cells where incubated with doxorubicin it 
accompanied by their low survival rate – 57,14%, the 
differences were significant in comparison with 
positive control (р≤0.01) (table 1). 




The Name of Probe Optical density, 
a.u. 
1 Blanks 0.018±0.002 
2 Positive control group 0.053±0.008 
3 Negative control group 0.037±0.005 * 
4 Wells with culture medium 
containing cytosar 
0.047±0.01 # 
5 Wells with culture medium 
containing doxorubicin 
0.038±0.005 * 
6 Wells with culture medium 
containing trimetazidin 
0.046±0.007 # 
* – differences are significant in comparison with 
positive control group (р≤0.01); # – the same with 
negative control group (р≤0.01). 
It is known that MTT assay is based on an ability 
of mitochondrial dehydrogenases to convert water 
soluble 3-(4, 5dimethylthiazol-2-y1)-2,5-diphenyl 
tetrazolium bromide into formazan, which crystallizes 
inside the cell [22, 23, 24]. The obtained results of 
MTT assay conforms with the results of 
mitochondrial activity study with fluorescence probe 
MitoTracker Red CMXRos. Cytosar and trimetazidine 
stimulate mitochondrial activity due to activation of 
intracellular metabolic processes, while doxorubicin 
inhibits both mitotic activity and intracellular 
metabolic processes. 
Conclusions 
1. Medicinal preparations from the antitumor 
antibiotics group decrease mitochondria activity 
regardless of the cell state unlike antitumor 
metabolites. 
2. Medicinal preparation trimetazidine increases 
cardiac fibroblasts mitochondrial activity. 
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